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The use or misuse of statins in critically ill patients recently attracted the attention of intensive care clinicians.
Indeed, statins are probably the most common chronic treatment before critical illness and some recent
experimental and clinical data demonstrated their beneficial effects during sepsis, acute lung injury (ALI)/acute
respiratory distress syndrome (ARDS), or after aneurismal subarachnoidal hemorrhage (aSAH). Due to the
heterogeneity of current studies and the lack of well-designed prospective studies, definitive conclusions for
systematic and large-scale utilization in intensive care units cannot be drawn from the published evidence.
Furthermore, the extent of statins side effects in critically ill patients is still unknown. For the intensive care clinician,
it is a matter of individually identifying the patient who can benefit from this therapy according to the current
literature. The purpose of this review is to describe the mechanisms of actions of statins and to synthesize the
clinical data that underline the relevant effects of statins in the particular setting of critical care, in an attempt to
guide the clinician through his daily practice.
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Background
The use or misuse of statins in critically ill patients re-
cently attracted the attention of intensive care clinicians
for several different reasons. First, statins are probably
the most common chronic treatment before critical ill-
ness. These lipid-lowering drugs are widely prescribed
(18 million prescription purchase in France and 173.7
million in the United States) [1,2], because they improve
survival in patients with cardiovascular disease [3,4] and
in apparently healthy persons without hyperlipidemia
but with elevated high-sensitivity C-reactive protein
levels [5]. Second, the adverse effects of statins, includ-
ing liver test abnormalities and rises in the plasma levels
of creatine kinase, explain the withholding of statin
treatment during the stay in intensive care units. Third,
the continuation or discontinuation of a previous statin
therapy use during hospitalization could be associated
with specific effects. The importance of a prior statin
treatment must be placed in the context of the paper by
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reproduction in any medium, provided the origwith acute arteriosclerotic cardiovascular disease [6].
Heeschen et al. investigated the effects of statins on the
cardiac event rate in 1,616 patients of the Platelet Recep-
tor Inhibition in Ischemic Syndrome Management
(PRISM) study who had coronary artery disease and
chest pain during the previous 24 h. If the statin therapy
was withdrawn after admission for acute coronary syn-
drome, cardiac risk increased compared with patients
who continued statins (2.93 [95% confidence interval
(CI), 1.64–6.27]; P= 0.005) and tended to be higher com-
pared with patients who never received statins (1.69
[95% CI, 0.92–3.56]; P= 0.15). This was related to an
increased event rate during the first week after onset of
symptoms and was independent of cholesterol levels. In
a multivariate model, continuation of statin therapy
(P= 0.008) was an independent predictor of favorable
outcome. Fourth, some experimental and clinical data
demonstrated beneficial effects of statins during sepsis,
acute lung injury (ALI)/acute respiratory distress syn-
drome (ARDS), or after subarachnoidal hemorrhage
(SAH) in relation with the so-called pleiotropic effects of
this class of drugs [7]. These effects could benefit to
these patients in relation with the associated anti-
inflammatory, immunomodulatory, antithrombotic, and
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vidual inflammatory mediators, they could modulate the
overall magnitude of the inflammatory response [8]. A
recent study reported that preadmission use of statins
was associated with a reduction in 30-day and 1-year
mortality of a cohort of 12,483 critically ill patients [9].
Even patients under statin treatment developing multiple
organ dysfunction syndrome (MODS) seems to have a
better outcome than age- and sex-matched MODS
patients without statin therapy [10].
These impressive findings underline the need for a review
of the mechanisms of action and clinically relevant effects
of statins in the particular setting of critical care. Therefore,
we reviewed the literature retrieved on PubMed, using the
following key terms: statins; hydroxymethylglutaryl-CoA re-
ductase inhibitors; intensive care; ICU; critical care; sepsis;
infection; ALI; ARDS; stroke; subarachnoid hemorrhage.
Mechanisms of action of statins
Figure 1 displays schematically the mechanisms of action of
statins. Intracellularly, statins inhibit the 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA reductase),
thereby decreasing the synthesis of cholesterol. Besides this
well-known effect, the inhibition of mevalonate synthesis by
statins also results in the decrease of intermediary products
of this cascade, including farnesylpyrophosphate and gera-
nylgeranylpyrophosphate. These molecules are involved in
the activation by isoprenylation of small GTP-binding pro-
teins (Roc, Rho, and Ras). This event triggers the activation
of transcription factors, which are involved in the pleio-
tropic effects of statins. The functional consequences of
these actions are numerous and include anti-inflammatory
and anti-oxidant effects, immune modulation, antithrombo-
tic effects, protection of the endothelial function, and acti-
vation of vitamin D.
Anti-inflammatory and immunomodulatory effects
The inhibition of mevalonate synthesis by statins results
in a lesser activation of the small GTP-binding proteins,
which play a key role in the activation (molecular on/off
switches) of intracellular inflammatory signalling path-
ways. Consequently, the response of the inflammatory
intracellular signalling pathway upon stimulation is
reduced, although not fully abolished. In particular, the
activation of nuclear factor kappa B, mitogen-activated
protein kinase (MAPK), and phosphatidylinositol-3 kin-
ase (PI3K) systems by isoprenylated protein kinases is
blunted (Figure 1). Therefore, the expression of cyto-
kines, acute phase proteins, chemokines, adhesion mole-
cules, and enzymes is partially inhibited in the presence
of statins (Figure 2) [11]. By their action on chemokines
and adhesion molecules, statins directly influence leuco-
cyte function by a direct inhibition of the major histo-
compatibility complex type II (MHC II) gene of antigenpresenter cells [12] and an allosteric block site of the
lymphocyte function-associated antigen (LFA-1) [13,14],
which has a significant role in lymphocyte adhesion and
activation. Statins also decrease the expression of Toll-
like receptor 4 (TLR4) [15–17], possibly by an alteration
in cholesterol-rich membrane domains as observed in
brain plasma membranes [18]. The clinical consequences
of these anti-inflammatory and immunomodulatory
effects will be discussed later in this review.
Vascular effects: Antithrombotic effects and preservation of
endothelial function
The cardiovascular effects of statins were the major focus
of clinical research, because the beneficial effects of statin
therapy were reported in patients with cardiovascular dis-
eases. Besides the prevention of atherosclerosis by their
lipid-lowering properties, statins also modulate coagulation
and exert antithrombotic effects via a number of mechan-
isms (Figure 2), including a decrease in the activity of plate-
lets, an increase in the tissue plasminogen activator and a
decrease of its inhibitor, and an enhancement in the expres-
sion and functional activity of thrombomodulin, an essen-
tial cofactor for protein C activation [19]. Statins might
thus enhance fibrinolysis by its effect of protein C.
Endothelial function also is preserved by statins, in re-
lation with the maintenance of endothelial constitutive
nitric oxide synthase (NOS) activity. On the other hand,
excessive vasodilatation, loss of systemic vascular resist-
ance, and vascular leak could be prevented by the inhib-
ition of the inducible isoform of NOS [20–22].
Antioxidant
Oxidative stress is defined by an imbalance between
increased levels of reactive oxygen species (ROS) and a
low activity of antioxidant mechanisms. An increased
oxidative stress can induce damage to the cellular
structure and potentially destroy tissues. Therefore, the
prevention of oxidative stress is probably desirable in
critically ill patients to minimize the risk of new organ
failures [23–26]. Statins exert antioxidant effects by the
inhibition of the NADPH oxidase [27]. In case of cellu-
lar hypoxia and reoxygenation, the activation of heme
oxygenase by statins could represent a protective mech-
anism against oxidative stress-related cellular damage
[28–31].
Vitamin D
Cells of the innate and adaptative immune system ex-
press the vitamin D receptor and respond to stimulation
by 1,25-dihydroxyvitamin D [1,25(OH)2D] [32], the ac-
tive form of vitamin D. Moreover, 1,25(OH)2D leads to
enhanced expression of human cathelicidin, which is an
endogenous antimicrobial peptide active against a broad
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Figure 1 Effects of statins on the cholesterol biosynthesis pathway. HMG-CoA reductase inhibition by statins reduces intracellular
mevalonate levels. Consequently, not only cholesterol levels are reduced but also the intermediary products farnesylpyrophosphate and
geranylgeranylpyrophosphate. These latter two provide binding sites for protein isoprenylation, and activation.
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form, 25-hydroxyvitamin D [25(OH)D] [34,35], by a
mechanism that is still unclear, but could have beneficial
effects on infection control [36,37].
Comparison with corticosteroids
Table 1 compare the anti-inflammatory, immunomodu-
latory, antioxidant, and endothelial effects of statins and
corticosteroids. Besides some minor differences in their
respective effects, the major distinction lies into the time
to onset of action. On the opposite of corticosteroids of
which antiinflammatory effects can be seen after less
than 24 hours of treatment, statins only achieve a meas-
urable anti-inflammatory effect after 7–14 days of treat-
ment [38,39]. This delayed effect seems to make theman unlikely candidate for suppressing systemic inflam-
mation in the acute phase of sepsis, as documented by
two recent studies that found no reduction in markers
of inflammation [40,41].
Effects of statin therapy during critical illness
Although possible effects of statins might influence the
outcome of patients with other conditions, documented
effects were reported during sepsis, ALI/ARDS, and
after SAH.
Sepsis
Sepsis is characterized by systemic inflammation and dysre-
gulation of the coagulation cascade and remains a major
source of morbidity and mortality in ICUs [42–45]. The
Figure 2 Pleiotropic effects of statins. Statins have anti-inflammatory, immunomodulatory, antithrombotic, and antioxidant properties found
independently of their lipid-lowering properties. Because statins do not target individual inflammatory mediators, they could modulate the overall
magnitude of the inflammatory response.
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effects of statins could be beneficial during sepsis. The first
encouraging clinical observations of improved outcome in
septic patients receiving statins fostered the conduct of re-
search in experimental models of sepsis.
Experimental studies
Two studies on animal models evaluated the effect on mor-
tality of statins given twice before the induction of sepsis.
Both studies demonstrated an improved survival in animals
treated with statins. Ando et al. [46] showed that cerivasta-
tin pretreatment of mice at 12 and 1 hour before lipopoly-
saccharide (LPS)-induced sepsis improved the rate of 7-day
survival from 26.7% in nonpretreated group to 73.3% in
cerivastatin-pretreated group. Merx et al. [47] evaluated the
effects of statins given at 18 and 3 hours before polymicro-
bial sepsis using a rodent model of caecal ligation and
puncture (CLP) and found a median survival time extended
to 108 hours from 28 hours in untreated mice. This im-
provement in the survival rate of simvastatin-treated mice
was associated with a complete preservation of cardiac
function at 20 hours and a preserved responsiveness to
dobutamine, in contrast to the untreated group, whosecardiac function and responsiveness to dobutamine were
severely impaired.
Another rat study of endotoxic shock [21] confirmed an
enhanced vascular responsiveness after simvastatin pre-
treatment 20 minutes before LPS. The impaired pressor re-
sponse to phenylephrine was preserved compared with rats
treated with untreated animals.
Only one animal study evaluated the effect of various sta-
tins after the onset of sepsis [48]. Statin treatment was
initiated 6 hours after CLP, when profound hemodynamic
alterations were present. Survival time was only 23±1.2
hours in the untreated group, whereas it was extended to
39±3.9 hours after treatment with atorvastatin, to 40±4.2
hours after pravastatin, and to 37±3.6 hours after simvasta-
tin (all P< 0.05 versus untreated). No change in the sur-
vival time was observed after fluvastatin. Cardiac output
measured at 20 hours after sepsis induction remained stable
in CLP mice treated with atorvastatin, pravastatin, or sim-
vastatin after sepsis induction (P=NS vs. preoperative),
whereas it decreased significantly in placebo or fluvastatin-
treated mice. The responsiveness to catecholamines, in-
cluding dobutamine was restored in CLP mice by treatment
with atorvastatin, pravastatin, or simvastatin.
Table 1 Statins and corticosteroids
Effects Statins Corticosteroids
Anti-inflammatory # CRP# Chemokine release (MCP-1, RANTES)#
Cytokines (IL-1β, TNF α, IL-6, IL-8)#
Adhesion molecule (P-selectin, VLA 4,
CD11a, CD11b, CD18)
# CRP# Chemokine release (MCP-1, RANTES)#
Cytokines (IL-1β, TNF α, IL-6, IL-8) but " IL-10,
one of the major anti-inflammatory cytokines#
Adhesion molecule (ICAM-1, ELAM-1)"Production
of anti-inflammatory monocyte subtype.
Immunomodulatory # MCH II expression and activity.#
TLR-4 expression.## Proliferation of
monocytes and macrophages.#
Lymphocytes T activation
" MCH II expression on monocytes and eosinophiles.#
CD 14 expression on monocytes# Complement activation.#
Proliferation of lymphocytes.# Neutrophils aggregation and
chemotactism." Apoptosis of mature lympho T, eosinophils,
endothelial cells and precursors of dendritic cells, but #
apoptosis of neutrophils." Phagocytosis of apoptic neutrophils.
Endothelial function # iNos expression# Leucocyte adhesion # iNos expression# Leucocyte adhesion# Synthesis of
COX-2, PGE-1 and prostacyclin# Production of Vascular
endothelial growth factor" Sensitivity to α-agonist





#Platelet activation and aggregation.
Comparison between the anti-inflammatory, immunomodulatory, endothelial, antioxidant, and antithrombotic effects of statins and corticosteroids.
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Cohort studies
A meta-analysis summarizing the effects of statins on
mortality in patients with infection and/or sepsis [49]
seems to support the hypothesis of a protective effect of
statins during sepsis.
The analysis included 20 studies (18 cohort studies (12
retrospective and 6 prospective), 1 matched cohort
study, and 1 randomized control trial). Of those 20 stud-
ies, 15 showed a decreased mortality in patients receiv-
ing statins with adjusted odds ratios (ORs) ranging from
0.06 to 0.75 [50–64]. Four studies showed a trend to-
ward a benefit from statins although not reaching statis-
tical significance [65–68]. Only one study reported an
increased mortality in patients taking statins [69].
The primary meta-analysis regarding mortality from
any cause at different time, according to 20 studies that
pooled 265,558 patients, demonstrated a significant pro-
tective effect from statins in patients with infection and/
or sepsis compared with no statin treatment or placebo
(OR, 0.49; 95% CI, 0.37–0.61) [50–69].
This meta-analysis supports the hypothesis of a protective
effect of statins during sepsis [49]. However, besides limita-
tions regarding the heterogeneity and design of the ana-
lyzed studies and exposure definition, the handling of
potential sources of bias and confounding, such as the
healthy user effect or indication bias, limits the interpret-
ation of these data. A recent prospective cohort study, spe-
cifically designed to avoid those bias, found no evidence of
a protective effect for statin use on clinical outcomes [40].
This study enrolled 1,895 subjects hospitalized with
community-acquired pneumonia. It first compares sub-
jects with prior statin use with those with no prior useand then compares continued in-hospital therapy with
no prior use or no in-hospital use. There were no differ-
ence in severe sepsis risk between statin users and nonu-
sers for prior (30.8% vs. 30.7%, P= 0.98) or continued
statin use (30.2% vs. 30.8%, P= 0.85) in univariate ana-
lyses and after adjusting for patient characteristics and
propensity for statin use. Interestingly, users whose sta-
tin was discontinued in the hospital had nearly twice the
mortality of those whose statin was continued (15.3% vs.
7.9%, P= 0.048). After accounting for likelihood of statin
use by including a propensity score in each model, there
was no detectable benefit of either prior (adjusted OR,
0.9; 95% CI, 0.63–1.29; P= 0.57) or continued statin use
(adjusted OR, 0.73; 95% CI, 0.47–1.13; P= 0.15).
First, in this study statin users were universally more
likely to have healthy user indicators (being insured, liv-
ing at home, being of good functional status, receiving
vaccinations, taking daily aspirin, and quitting smoking)
that can positively influence mortality in CAP. As these
statin users’ characteristics are supported by other work
in this area [70–72], this healthy-user effect may account
for better outcomes shown in previous studies [50–64].
Second, this analysis refutes prior studies that support
a protective effect of in-hospital ongoing statin therapy
probably due to indication bias. Indeed, the decision to
continue statin in the hospital depends on how sick the
patient is and whether they are able to take medications
by mouth. In this study, the inclusion of propensity for
continued statin use in the mortality models universally
moved the adjusted OR closer to unity and the p value
toward greater degrees of insignificance, suggesting no
association between 90-day mortality and cessation of
statin therapy.
De Loecker and Preiser Annals of Intensive Care 2012, 2:19 Page 6 of 12
http://www.annalsofintensivecare.com/content/2/1/19These findings seem to be confirmed by a randomized,
placebo-controlled trial that does not support a benefi-
cial role of continuing preexisting statin therapy on sep-
sis and inflammatory parameters [41]. This small trial
tested the hypothesis that continuation of therapy with
statins influences the inflammatory response to infection
and that cessation may cause an inflammatory rebound.
One hundred and fifty patients on preexisting statin
therapy requiring hospitalization for infection were ran-
domized to receive atorvastatin (20 mg) or matched pla-
cebo. The primary end point was progression of sepsis
during hospitalization. The rate of decline of severe sep-
sis was similar between the groups (odds ratio, 1.17
[0.56-2.47], P= 0.7 day 3; 0.85 [0.21-3.34], P= 0.8 day 14)
and IL-6 and C-reactive protein declined in both groups
with no statistically significant difference (P= 0.7 and
P= 0.2, respectively). Hospital mortality was 6.6%, with
no difference between the groups (6 [8%] of 75 statin
group; 4 [5.3%] of 75 placebo group; not significant).
These observational trials studied the effects of
chronic treatment before infection. The effect of statin
treatment initiated just before the onset of sepsis a
patients at-risk population or even after the onset of sep-
sis were not assessed. Obviously, prospective, rando-
mized trials over acute statin therapy are needed.
Placebo-controlled, randomized trial
Until now, only one double-blind, placebo-controlled,
randomized trial has tried to determine whether acute
statin therapy reduces the incidence of severe sepsis in
patients with acute bacterial infection [73]. Unfortu-
nately, because of very slow recruitment rate, this study
was stopped prematurely after 10 months and enrolled
only 83 subjects compared with the 1,080 planned in an
estimated 24-month period. Several other clinical trials
are now underway to examine the potential clinical
benefit of statins in sepsis.
Ongoing clinical trials
Simvastatin and severe sepsis trial (SIMSEPT) will be
the first double-blind, randomized, placebo-controlled
trial of simvastatin (40 mg) in the treatment of severe
sepsis in humans. It will investigate the effect of simvas-
tatin on important inflammatory markers and monitor
the safety and feasibility of administering simvastatin to
patients with severe sepsis [74]. The STATInS trial is a
phase II, randomised, placebo-controlled study of the
safety, pharmacokinetics, and effect on inflammatory
marker levels of atorvastatin in intensive care patients
with severe sepsis [75]. Two other phase II trials are
evaluating simvastatin in adults hospitalized with sepsis
with the primary outcome being time to clinical stabil-
ity in one trial [76] and time to shock reversal in the
other [77].ALI/ARDS
ARDS is a disease of multifactorial etiology characterized
by aspecific morphologic lesion termed “diffuse alveolar
damage” (DAD) [78]. Current understanding places dys-
regulated systemic inflammation—with persistent eleva-
tion of circulating inflammatory and hemostasis markers
over time—as the central pathogenetic process for dys-
function and failure of vital organs, the leading cause of
(short- and long-term) morbidity and mortality in
patients with ARDS [79].
Even with the use of protective ventilation [80], the
damaged lung is still susceptible to ventilation-induced
injuries [81]. There is, therefore, an urgent need for
other strategies to improve clinical outcome in ALI/
ARDS [82]. Several observational studies suggested that
statins could represent a useful therapeutic adjunctive
modality, as a benefit of prior statin use was found in
patients with pneumonia [51,59,63].
Experimental studies
Animal studies have demonstrated that statins attenuate
lung injury in models, such as ischemia-reperfusion,
peritonitis, and aerosolized LPS [83–86]. In thirty
healthy volunteers, a double-blind study compared the
effects of a pretreatment with simvastatin 4 days before
LPS inhalation to placebo [87]. A lower neutrophil count
(3 × 105/ml [1.8-8.1] vs. 8.5 × 105/ml [4.4-16.2]; P= 0.05
vs. placebo) and activity in the alveolar space, partially
due to an increase in neutrophil apoptosis was found in
the bronchiolo-alveolar lavage fluid (BALF) of the sub-
jects randomized to simvastatin. The increase in alveolar
neutrophil apoptosis may be related to a reduced pul-
monary and systemic inflammation after LPS inhalation
compared with placebo. Interestingly, the simvastatin
pretreated group also demonstrated a reduction in
MMPs and tumor necrosis factor α concentrations in
the BALF. The decrease in MMP-7 (P= 0.03 vs. placebo)
could be particularly relevant, because this factor is
required for neutrophil influx during ALI [88].
Clinical data
Cohort studies
Most observational studies show a benefit of prior statin
use in patients with pneumonia, suggesting a potential
modulation in pulmonary inflammation [51,54,59,61–
63,89–91]. One observational [92] and one retrospective
[93] cohort study of patients with ALI/ARDS reported a
trend toward reduced mortality in patients who were re-
ceiving statins before hospitalization.
Placebo-controlled, randomized trials
Recently, Craig et al. [94] reported a randomized, double-
blinded, placebo-controlled trial in 60 patients with ALI.
Patients were receiving 80 mg of simvastatin or placebo
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Although the pulmonary anti-inflammatory effect of sim-
vastatin was confirmed early in the course of treatment
(2.5- to 3-fold reductions in BALF IL-8 and IL-6 concentra-
tions compared with placebo), there was no difference in
extravascular lung water index at day 7 (13.7 [7.1] vs. 13.4
[8.0] for placebo; P=0.9). Nonetheless, at day 14 the
simvastatin-treated group tended to achieve improved oxy-
genation index (P=0.08), reduction in plateau pressure
(P=0.09), and better lung injury score (P=0.12). Very
interestingly, nonpulmonary organ failures were favorably
influenced by simvastatin, as the coagulation, renal, and
cardiovascular components of the SOFA score were all sig-
nificantly improved at day 14 in the simvastatin group. The
preservation of endothelial function by statins was sug-
gested to account for the improvement in nonpulmonary
organ dysfunction. Interestingly, this study also shows that,
despite the precocity of the anti-inflammatory effects, a
prolonged treatment may be required for these effects to be
translated into improvements in lung function. If this study
has shown that simvastatin has an effect on systemic and,
to a lesser degree, pulmonary outcomes in patients with
ALI, it was not powered to detect a difference in duration
of ventilation or mortality. Table 2 compares the effects of
statins and low-dose corticosteroids versus placebo on the
ventilatory status and outcome of patients with ARDS
[95,96].
Ongoing clinical trials
The National Institutes of Health Acute Respiratory Dis-
tress Syndrome Network is currently recruiting patients
with sepsis-induced ALI into the Statins for Acutely
Injured Lungs study (SAILS) [97], which is powered for
clinical outcomes measures with an estimated enroll-
ment of 1,000 patients and a completion date estimated
for September 2012.
Statins and aneurismal subarachnoid hemorrhage (aSAH)
Vasospasm and related delayed ischemic neurologic defi-
cits (DINDs) remain a major cause of morbidity and
mortality after aneurysmal subarachnoid hemorrhage
(aSAH). Current medical treatment options are limited
to triple-H therapy (hypertensive, hypervolemic, hemo-
dilution) [98] and calcium-channel blocker nimodipine
[99]. Potentially, statins might exert beneficial effects in
aSAH, as a result of the protection of endothelial func-
tion by an increased expression of endothelial NOS, by
the promotion of angiogenesis, by the prevention of ex-
cessive platelet activation, or via their antioxidant or
anti-inflammatory effects. Regardless of the underlying
mechanism, in the presence of statins the diameter of
the vasospastic vessels are increased, endothelial func-
tion is improved and most importantly, ischemia is pre-
vented [100].Clinical data
Meta-analyses of placebo-controlled, randomized trials
In 2008, a meta-analysis of three studies concluded that
in patients with aSAH, statins reduced the incidence of
vasospasm, DINDs, and mortality [101] However, this
meta-analysis was criticized for its methodology and in-
terpretation of results [102,103]. Recently, a meta-
analysis of four randomized [64,104–108], double-
blinded, placebo-controlled trials investigating the effects
of acute statin treatment on vasospasm, DINDs, and out-
come was performed, including 190 statin-naïve patients
with aSAH. For the analysis of the occurrence of tran-
scranial Doppler (TCD) vasospasm, data from three of
the four studies were available [106–108]. The overall
number of patients who had TCD vasospasm was 42 in
the statin group and 46 in the placebo group (pooled
relative risk (RR), 0.99; 95% CI, 0.66–1.48). The total
number of patients who developed DINDs was 20 in the
statin group and 39 in the placebo group, but this differ-
ence was not statistically significant (pooled RR, 0.57;
95% CI, 0.29–1.13). However, a subgroup analysis for the
type of statins showed that patients randomized to pra-
vastatin (n = 40) had a significant lower risk of DINDs
(RR, 0.17; 95% CI, 0.04–0.7) compared with placebo.
As for TCD vasospasm and DINDs, definitions used
for poor outcome were different in each study. In two
studies, functional outcome was assessed with the modi-
fied Ranking Scale (mRS) [106,107]. The Glasgow Out-
come Scale scores of the latter study were transformed
to a Rankin grading [108]. Furthermore, the timing of
measuring differed between groups either at discharge
or at 6 months. The overall number patients with poor
outcome was 38 in the statin group and 42 in the pla-
cebo group (pooled RR, 0.92; 95% CI, 0.68–1.24). The
results of this meta-analysis do not lend statistically sig-
nificant support to a beneficial effect of statins in
patients with aSAH.
Another meta-analysis of six RCTs concluded that sta-
tins reduced the occurrence of DINDs (OR, 0.38 (0.23-
0.65); P< 0.001) [106–112]. However, this analysis
included two RCTs in which patients were “pseudo-
randomized,” i.e., unblended or not placebo-controlled
[110,111]. When these two latter studies were omitted,
there was a larger heterogeneity in the effects of statins
on DINDs (I 2 = 47%).Cohort studies
If RCTs are clearly the preferred study design to assess
treatment efficacy, the small number of patients in these
RCTs may unbalance the baseline characteristics and,
thus, influence the results. The addition of observational
studies can increase greatly the sample size, thereby re-
ducing the chance of type II errors.
Table 2 Effects of statins and low-dose corticosteroids versus placebo on the ventilatory status and outcome of
patients with ARDS
















199 ± 76 199 ± 76 NS 256± 19 179± 21 0.006
LIS day 7 2 ± 0.78 2.1 ± 0.7 NS 2.14 ± 0.12 2.68 ± 0.14 0.004
Ventilator
free days
8.2 ± 8.1 9.1 ± 8.7 NS 16.5 ± 10.1 8.7 ± 10.2 0.001
Duration of
ventilation
18.6 ± 14.6 18.6 ± 14.6 NS 5 (3-8) 9.5 (6-19.5) 0.002 5 (0-64) 9.5
(0-63)
0.005





21 (70) 21 (70) NS 50 (79.4) 16 (57.4) 0.03 44 (80) 14 (58) 0.05
Hospital
stay





19 (63) 19 (63) NS 48 (76.2) 16 (57.1) 0.07
Data are presented as mean ± SD, no. (%), and median (interquartile range).
NS not significant.
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tional studies (five cohort, one case–control), including
1,542 patients of whom 385 received statins [109,112–
117]. Statin-use was not associated with any reduction
in DINDs (OR, 0.96 (0.71–1.31); P= 0.8), mortality
(OR 1.16 (0.78–1.73); P= 0.47) or poor neurological
recovery (OR, 1.2 (0.84–1.72; P= 0.31). When the
results of these six observational studies were com-
bined with those of the six RCTs, statins had no sta-
tistically significant effect.
Interpreting results about possible beneficial effects of
immediate statins therapy in statin-naïve patients follow-
ing aSAH is limited by small sample sizes and low to
moderate quality of available RCTs and very low quality
for observational studies. Some of the inconsistencies of
results may reflect substantial differences among studies
design.
Ongoing clinical trials
Four, registered, clinical trials are currently assessing the ef-
ficacy of statins aSAH. The SimvaSTatin in Aneurysmal
Subarachnoid Haemorrhage (STASH) trial [118] is a multi-
center, placebo-controlled, double-blinded, phase III trial
testing the hypothesis that Simvastatin (40 mg treatment
started within 96 hours of the ictus, for 3 weeks) will reduce
the incidence and duration of DINDs following subarach-
noid hemorrhage. The target enrolment is 1,600 patients,
with projected completion in February 2013.
Another study investigates the effect of statin therapy
on cerebral blood flow in patients with aSAH, using a
positron emission tomography [119]. A third study israndomizing 240 patients to 40 or 80 mg of simvastatin
or placebo, with presence of DIDs listed as primary end-
point [120]. Finally, a double-blind, placebo, randomized,
control trial with an estimated enrollment of 80 patients
is being conducted in Sao Paulo with clinical outcome at
6 months being the primary endpoint [121].
Conclusions
Summary and interpretation
Several lines of evidence from both experimental and
clinical studies suggests that statin use during sepsis,
ALI/ARDS, and aSAH is beneficial. However, definitive
conclusions cannot be drawn from the published evi-
dence. Indeed, there is considerable heterogeneity of
studies in type of statins, dosage, and duration of statin
administration and case-mix. Moreover, many works are
retrospective, providing less strong evidence than well-
designed prospective studies. Waiting for the results of
placebo-controlled, randomized trials, the intensive care
use of statins should be cautious.
Indeed, the impact of statins side effects on large-scale
utilization in intensive care is still not known. If serious side
effects of statins, such as myopathy and rhabdomyolysis,
are very rare in the general population (0.01% and 0.003%
respectively) [122], the incidence and severity of these ad-
verse effects could be higher in the critically ill. The lack of
parenteral formulation of statins is another limitation, be-
cause the gastrointestinal absorption of statins might be
impaired during critical illness. Furthermore, the pharma-
cokinetic profile could be altered during sepsis. Kruger
et al. [123] demonstrated that when critically ill patients
De Loecker and Preiser Annals of Intensive Care 2012, 2:19 Page 9 of 12
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plasma concentration peaked approximatively 18 times
higher than those of healthy volunteers. Drage et al. [124]
administered 40 mg of simvastatin to 27 critically ill
patients, who also demonstrated higher plasma levels of
both simvastatin and its active metabolite compared with
healthy volunteers. Whether supratherapeutic plasma levels
of statins in critically ill patients translates to an increased
toxicity and requires adjustment remains unclear, especially
when renal clearance might be impaired. The hepatic meta-
bolization of statins might be altered as well, thereby in-
creasing the risk of toxicity. Similarly, the metabolization of
statins by the cytochrome P450 3A4 system may interfere
with other medications commonly used in the ICU (i.e.,
amiodarone, macrolide antibiotics).
The right dosage is thus still undefined, as well as the
right statins agent. Indeed, the type of statins used in cohort
observational studies was very heterogeneous, raising the
question of the similarity between the effects of the differ-
ent agents. The majority of randomized, placebo-controlled
trials plans to use simvastatin. As the other statins, simvas-
tatin is metabolized by the liver, but its metabolite is cleared
by the kidney and could accumulate in case of renal dys-
function, thereby increasing the risk of toxicity and in par-
ticular of clinical myopathy [125].
In sepsis, a major issue is the timing when statins should
be started and stopped. An excessive inhibition of the in-
flammatory process could increase the susceptibility to sec-
ondary infections related to immune dysfunction [126–
129]. It has been observed that more than 80% of nonsur-
viving patients die late after initial resuscitation in an im-
munosuppressive state, whereas patients who survive are
those who spontaneously recover immune function [130].
Anti-inflammatory therapies may be harmful in septic
patients [131,132]. This may be particularly true for statins
that, above their anti-inflammatory effects, present suppres-
sive effects on leucocytes. Indeed, monocyte deactivation is
thought to be responsible for the impairment in antigen
presentation and the decreased capacity to mount a proin-
flammatory reaction upon a secondary bacterial challenge
[133]. As prophylaxis or in the very early management, the
anti-inflammatory effects of statins may be protective in
sepsis, but as the disease progress and multiorgan dysfunc-
tion becomes established, its side effects may prevail. Given
these data, the objective of an ideal sepsis treatment should
be to define the right action (i.e., blocking sustained inflam-
matory response, stimulate innate or adaptative immunity,
restoring altered function) at the right time (early or
delayed treatment) in the right patient (individualized ther-
apy) [134].
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